This short-term study of the relative importance of estrogen and progesterone receptors shows that progesterone receptor correlates better than estrogen receptor with tumor recurrence regardless of lymph-node status. Ufe-table analysis has effectively identified only two groups of patients that may be classified by progesterone receptor status alone. Progesterone-receptor negativity correlated well with tumors of histological Grade Ill; estrogen-receptor positivity correlated with Grade I and II tumors. The earlier recurrence of Grade Ill breast tumors may explain why progesterone receptor is a better prognostic indicator than estrogen receptor in shortterm studies.
better prognostic indicator than estrogen receptor in shortterm studies.
Measurements
of estrogen receptors (ER) and progesterone receptors (PR) in primary breast cytosols are widely used as indicators of responsiveness to subsequent endocrine therapy (1). This is particularly true for PR after tamoxifen "priming" of the tumor (2) . Lymph-node status and the histological grade of the primary tumor (3) are established as good predictors of disease-free interval, but the role of ER and PR in predicting the likelthood of recurrence is more controversial.
Factors such as the cutoff value used to distinguish between positive and negative results (4), the length of follow-up (5) , and subsequent therapy after primary mastectomy (6) have all been shown to influence the performance of ER and PR as predictors of recurrence or non-recurrence.
Here we report our investigation of the relative importance of ER and PR as predictors of disease-free interval (i.e., non-recurrence) in 179 patients with primary cancer of the breast during three years of follow-up.
PatIents and Methods

Patient Selection and Treatment
We successfully followed, for three to 36 months, 179 of 275 casesof primary cancer of the breast in whom receptor analysis was performed. Full menopausal and histological details of these patients were available (see Table 1 ). All presented with resectable breast cancer, and initial postmastectomy therapy was based on local lymph-node status. If the lymph node contained tumor, the patients were given radiotherapy;
if not, a "wait and see" policy was adopted.
Receptor Assays
The breast-tumor cytosolic fraction was prepared and the ER and PR assay were performed as previously described (7). The latter, in essence, is as follows. The between-batch coefficient of variation (CV) for each assay was 13%, a value achieved by use of lyophilized human breast tissues as quality-control material. Lymph-node status and the grade of the tumor were determined histologically, the latter by the method of Bloom and Richardson (3).
Statistics
P-values for Figure 1 were calculated by the log-rank test
(8).
Results Table 1 shows the distribution of these 179 patients with breast cancer, categorized by their receptor content (positive/negative) in relation to menopausal status, histological grade of primary tumor, lymph-node status, and recurrence rate. Of the post-menopausal patients, significantly more were ER-positive (73%) than were PR-positive (41%) (P <0.001). In both groups of patients with and without detectable tumor in the lymph nodes, most were ER-positive, 64% and 71%, respectively, while only 39% and 42%
were PR positive (P <0.001). Table 2 shows the distribution and recurrence rates of patients in the ER-positive and ER-negative groups and the PR-positive and PR-negative groups, the positive receptor groups having a lower overall recurrence rate than the negative receptor groups. Further division of the four groups by lymph-node status showed that where patients were lymph-node positive, the ER-or PR-positive and ER-or PRnegative groups had the same recurrence rates, whereas those patients who were lymph-node negative had a lower recurrence rate when ER-negative than when ER-positive.
Both receptors, individually and in combination, showed a correlation with the histological grade of the tumor (Table  3 ). There was no significant difference in receptor status of Grades I and II. In comparison, the group of tumors classified as histological Grade ifi had significantly fewer ERand PR-positives than in tumor Grades I and II and more ER-and PR-negatives.
The receptor phenotypes, ER+/PR+ and ER-/PR-, showed the same relationship to histological grades as did individual receptor groups, while tumors containing only one receptor type showed no significant difference between the histological grades. Recurrence rates were significantly greater (P <0.005) in patients who were negative for PR than those who were positive, irrespective of ER status.
Disease-free interval analysis of the four phenotypes (Figure 1) showed the PR-positive patients to have a significantly longer disease-free interval than PR-negative patients (P <0.005). Patients who were ER-positive but PRnegative were not significantly different from patients with neither receptor (P <0.01), and patients negative for ER but positive for PR showed a disease-free interval similar to that for patients positive for both receptors. It should be noted that there were only five patients in this former group. As the cutoff value between ER-and PR-positive and negative results may influence the outcome of this type of study, we investigated the effect on recurrence rate of changing this value. There was a difference in recurrence of less than 4% in each group of patients over a cutoff range between 3 and 100 fmol per milligram of cytosol protein.
DiscussIon
In this study there was no pre-selection of patients on the basis of tumor grade or clinical stage of the disease. They all presented at a U.K. District General Hospital with primary breast cancer that was thought to be suitable for mastectomy. After surgery the primary tumors were graded histologically and analyzed for receptor content. Subsequent treatment was determined by lymph-node status, radiotherapy being instigated if there was spread to the lymph nodes; if not, a "wait and see" policy was adopted. The study describes a relatively short (three year) followup, A longer follow-up has shown receptor status to be less prognostically significant (5), probably owing to the long natural history of the disease (9) .
In this study ER and PR were regarded as positive if values exceeded 10 and 15 fmol per milligram of protein, respectively. Varying these cutoff values between 3 and 100 fmol per milligram of protein resulted in changes of <4% in ER-and PR-positive groups of patients. Most workers use a cutoff value well below 50 fmol/mg, which suggests that the different cutoff values used are unlikely to have significantly influenced the conclusions on the prognostic potential of receptor results. The factor mainly influencing the prognostic usefulness of the receptor is whether or not there is unequivocal detection of the receptor.
The distribution of patients according to receptor status and other characteristics showed significant variations within the groupings (Table 1) . This was reflected in the ERpositive and PR-positive relationship to lymph-node status, histological grade of tumor, and recurrence rates for the tumor.
PR correlated well with tumor recurrence, PR positivity indicating a significantly better prognosis. This was true with both positive and negative lymph-node status, while ER negativity correlated well with recurrence only in patients with positive lymph-node status (Table 2) . Progesterone receptor negativity correlated well with those tumors classified as Grade 111,88% being PR negative, whereas ER gave a better discrimination of tumors classifled as Grades land 11,76% being ER positive (Table 3) . In a short-term study such as this one where Grade ifi tumors are likely to recur earlier than Grade I and 11tumors, PR may be expected to be a better prognostic indicator.
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When we compared ER and PR as prognostic indicators by life-table analysis, there were effectively only two groups of patients and these could be classified by PR status alone (Figure 1) . Patients who were ER-positivefPR-negative showed a similar pattern of disease-free interval to patients without receptors, and the small number of patients who were ER-negativefPR-positive had disease-free intervals similar to those who were positive for both receptors. This small group of ER-negative patients may have been misclassified because of interference of endogenous estrogen in the steroid binding assay, leading to false-negative results (10).
In conclusion, this short-term study has shown PR to be a better prognostic indicator than ER, mainly because of the poor prognostic outcome of patients with ER-positivefPRnegative tumors. This patient group may contain patients with defective binding of ER to the nuclear acceptor sites of the tumor cells, which hinders or prevents the subsequent production of estrogen marker-proteins such as PR. Methods that measure this defect directly eventually may prove more successful in identifying those patients whose tumors are truly hormone dependent (11).
